# Bioequivalence Study of BGM0504 Injection

> **NCT07382908** · PHASE1 · RECRUITING · sponsor: **BrightGene Bio-Medical Technology Co., Ltd.** · enrollment: 144 (estimated)

## Conditions studied

- Overweight/Obesity

## Interventions

- **DRUG:** BGM0504 Injection multi-dose pen
- **DRUG:** BGM0504 Injection single-dose pen
- **DRUG:** BGM0504 Injection single-dose pen

## Key facts

- **NCT ID:** NCT07382908
- **Lead sponsor:** BrightGene Bio-Medical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-23
- **Primary completion:** 2026-02-12
- **Final completion:** 2026-02-12
- **Target enrollment:** 144 (ESTIMATED)
- **Last updated:** 2026-02-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07382908

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07382908, "Bioequivalence Study of BGM0504 Injection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07382908. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*